Liver volumetry improves evaluation of treatment response to hepatic artery infusion chemotherapy in uveal melanoma patients with liver metastases

FIGURE 1.

FIGURE 2.

FIGURE 3.

FIGURE 4.

FIGURE 5.

Univariate and multivariate Cox proportional hazards regression model of evaluation of treatment response to hepatic artery infusion chemotherapy by RECIST 1_1 and liver volumetry

Analysis				Univariate			Multivariate
Covariate	Category	n	Median OS (95% CI)	HR (95% CI)		p	HR (95% CI)		p
RECIST 1.1a	SD	122	14.6 (11.9–17.3)		Reference			Reference
	PD	21	8.5 (5.5–11.5)	2.11	1.29–3.45	0.003	1.19	0.92–1.55	0.184
Liver volumetry	SD (liver volume decreases or increases up to max. 10%)	103	15.9 (12.7–19.1)		Reference			Reference
	PD (liver volume increases more than 10%)	40	6.6 (4.4–8.8)	1.84	1.51–2.26	<0.001	1.77	1.43–2.19	< 0.001

Comparison of median overall survival (mOS) differentiated by different changes in liver volume before and after first hepatic artery infusion chemotherapy

Liver volume change			Log-rank (Mantel-Cox) test
			Increase 0–10%		Increase 10–20%		Increase > 20%
	N	mOS [months]	Chi-square	p	Chi-square	p	Chi-square	p
Decrease	53	15.9	0.1	0.7852	14.2	0.0002	32.3	< 0.0001
Increase 0–10%	50	15.4			15.8	< 0.0001	33.4	< 0.0001
Increase 10–20%	25	7.9					1.9	0.162
Increase > 20%	15	5.7

Median overall survival and accordance of treatment response evaluation by RECIST 1_1 and liver volumetry with a threshold of 10% increase in liver volume

Liver volumetry
	SD (Liver volume decreases or increases up to max. 10%)	PD (Liver volume increases more than 10%)	Total
RECIST 1.1 criteria
SD	16.6 months (n = 95)	6.6 months (n = 27)	14.6 months (n = 122)
PD	12.8 months (n = 8)	7.7 months (n = 13)	8.5 months (n = 21)
Total	15.9 months (n = 103)	6.6 months (n = 40)	12.6 months (n = 143)

Results of evaluation of treatment response to hepatic artery infusion chemotherapy (HAIC) by RECIST 1_1 and liver volumetry

	Before first HAIC	After first HAIC	p-value
RECIST 1.1a
(Sum of) longest diameter(s) of target lesion(s) [mm]
Total study cohort (n = 143)	48.6 (IQR 36.3–69.2)	50.8 (IQR 35.3–76.5)	0.0008
SD (n = 122)	47.7 (IQR 36.2–70.5)	48.0 (IQR 34.5–71.1)	0.3485
PD (n = 21)	55.2 (IQR 34.3–68.9)	73.0 (IQR 46.5–85.3)	< 0.0001
Liver volumetry
Total liver volume [ml]
Total study cohort (n = 143)	1735 (IQR 1431–2189)	1780 (IQR 1461–2329)	< 0.0001
SD (liver volume decreases or increases up to max. 10%) (n=103)	1678 (IQR 1426–2176)	1714 (IQR 1430–2151)	0.6691
PD (liver volume increases more than 10%) (n=40)	1903 (IQR 1481–2529)	2203 (IQR 1692–2946)	<0.0001